Why the study?
This study was conducted to compare pharmacokinetic characteristics, assess food effects, and evaluate the bioequivalence of two fixed-dose combinations of lisinopril/amlodipine besylate in healthy Chinese subjects.
Are the test and reference fixed-dose combinations of lisinopril/amlodipine besylate bioequivalent in healthy Chinese subjects?
Are the test and reference fixed-dose combinations of lisinopril/amlodipine besylate bioequivalent in healthy Chinese subjects?
The test and reference fixed-dose combinations of lisinopril/amlodipine besylate are bioequivalent and well tolerated in healthy Chinese subjects.
Supports substitution of the test formulation in practice; confirms bioequivalence of lisinopril/amlodipine FDCs in Chinese subjects.
Background:This study was conducted to compare the PK characteristics, food effect and evaluate the bioequivalence between two fixed-dose combinations of lisinopril /amlodipine besylate in healthy Chinese subjects. Methods: A single center, randomized, open-label, single-dose, crossover bioequivalence study was designed in healthy Chinese subjects under both fasting and fed conditions. Cmax and AUC were used to evaluate bioequivalence. Adverse events were recorded. Results: 75 healthy subjects completed the study. The 90% confidence intervals of the ratio of geometric means of Cmax and AUC0-∞ of lisinopril and amlodipine fell within 0.80-1.25. A fat-high breakfast produced significant alteration in the Cmax and AUC of lisinopril after a dose of either reference or test drug. No severe adverse events were observed. Conclusion: The trial demonstrated that the test and the reference drug of fixed-dose combinations of lisinopril /amlodipine besylate were bioequivalent and well tolerated under fasting and fed condition
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: